- £46.60m
- £43.10m
- £6.00m
UK private hospital use Speedboat for cancer case
Brief: Creo Medical Group Expects 40%-60% Full Year Revenue Growth In FY2026
Positive Q1 trading update
Brief: Creo Agrees To Sell Manufacturing Operations To Current Manufacturing Operations Management
UK's Creo Medical FY25 revenue rises 50%
FY25 Trading Update
Award of Shares under Share Incentive Plan
Corrected: BRIEF-Creo Medical H1 Adjusted EBITDA GBP -7.2 Million
Unaudited results for the six months ended 30 June
Holding(s) in Company
Notice of Results
Director/PDMR Share Dealing
Speedboat® patient testimonial
Award of Shares under SIP and Director Dealings
Brief: Creo Medical Says Tracking On Plan For 40% To 60% Revenue Growth For FY
H1’25 Trading Update
MicroBlate™ Flex begins lung tumour clinical study
PDMR Options Revision
AGM Statement and Directorate Changes